Senolytics are one of the most genuinely exciting ideas in aging research. The pitch is elegant: as we age, we accumulate worn-out "zombie" cells that refuse to die and leak inflammation into the tissue around them, and if you could selectively clear those cells, you might slow the machinery of aging itself. In mice, doing exactly that has produced some of the most striking results in the whole longevity field. Naturally, the supplement world moved fast, and fisetin, a flavonoid found in strawberries, is now sold everywhere as the accessible senolytic you can take today. So it is worth asking the plain question the marketing skips: what has actually been shown in humans? The honest answer is more sobering, and more interesting, than either the hype or the dismissal.
The short answer
The dramatic lifespan and healthspan results are all in mice. In humans, there are only a handful of tiny, short trials, and nearly all of them used a prescription drug combination (dasatinib plus quercetin), not fisetin. Those trials showed senolytics can lower markers of senescent cells and are feasible to run, but a placebo-controlled follow-up did not reproduce an early benefit, an Alzheimer's pilot found nothing, and the best-designed trial missed its main goal. No human study has ever measured lifespan or healthspan. And fisetin, the one you can actually buy, has no published human efficacy data at all.
Senolytics, senescent cells, and where fisetin fits
As cells age or get damaged, some enter a state called senescence: they stop dividing but refuse to die, and they start secreting a cocktail of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. A few of these cells are useful (they help wound healing and block tumors), but as they pile up with age they are thought to drive chronic inflammation and tissue decline. That is the theory of aging these compounds target.
A senolytic is a compound that selectively kills senescent cells while sparing healthy ones. Two candidates dominate the conversation. The first is fisetin, a plant flavonoid that laboratory screens flagged as the most potent single-compound senolytic among common flavonoids, and which you can buy over the counter. The second is a pairing called dasatinib plus quercetin (usually written D+Q), where dasatinib is a prescription leukemia drug and quercetin is a flavonoid cousin of fisetin. Here is the twist that frames everything below: almost all of the human evidence is for D+Q, the combination you cannot buy, while fisetin, the one you can, carries almost none. For a deeper look at fisetin the molecule itself, its poor absorption, and the hit-and-run protocol, see our companion piece on fisetin the senolytic flavonoid.
Why everyone is excited: the mouse data
The enthusiasm is not made up. In animals, clearing senescent cells has produced results that would be extraordinary if they held in people.
What the landmark animal studies showed
In two Nature papers, Baker and colleagues used a genetic switch to delete senescent cells in mice: the 2011 study delayed the onset of age-related disorders, and the 2016 study, in normally aging mice, extended median lifespan and slowed the decline of several organs. Then came the drugs. Xu and colleagues (Nature Medicine, 2018) showed that intermittent dasatinib plus quercetin improved physical function and increased post-treatment survival in old mice, and Yousefzadeh and colleagues (EBioMedicine, 2018) found fisetin was the most potent of ten flavonoids tested and, given late in life, extended both median and maximum lifespan. These are genuinely important results. Two caveats matter: the dramatic Baker lifespan findings came from a genetic tool, not a pill, and every one of these studies was done in mice.
Baker 2011 (PMID 22048312) · Baker 2016 (PMID 26840489) · Xu 2018 (PMID 29988130) · Yousefzadeh 2018 (PMID 30279143). All animal or genetic-model studies.
This is the root of the marketing. A supplement seller can truthfully say "fisetin extended lifespan in a study" and let you assume it means people. It does not. The leap from a mouse living longer to a human doing so is exactly where the evidence gets thin, so the rest of this article is about that leap.
The human scoreboard, trial by trial
Here is every published human senolytic trial with results, laid out plainly. Notice three things as you read: the numbers are tiny, the endpoints are surrogate markers or short-term physical tests rather than lifespan, and the compound is dasatinib plus quercetin in every single one.
| Trial | Senolytic | Who | Design | What it found |
|---|---|---|---|---|
| Hickson 2019 | D+Q | 9 adults, diabetic kidney disease | Open-label, no placebo | Fewer senescent-cell markers in fat and skin. No kidney or clinical outcome measured. |
| Justice 2019 | D+Q | 14 adults, lung fibrosis (IPF) | Open-label pilot, no placebo | Walked farther and rose from a chair faster. Lung function did not change. |
| Nambiar 2023 | D+Q | 12 adults, IPF | Randomized, placebo-controlled | Feasible, but the physical-function gains did not beat placebo. More side effects than placebo. |
| Gonzales 2023 | D+Q | 5 adults, early Alzheimer's | Open-label pilot | Confirmed the drug reaches the brain. No change in amyloid, tau, senescence markers, or memory. |
| Farr 2024 | D+Q | 60 women, postmenopausal bone loss | Phase 2 randomized trial | Missed its main bone-marker goal. A signal appeared only in a post-hoc high-senescence subgroup. |
| Fisetin trials | Fisetin | Frailty, COVID-19, sepsis | Registered trials | No published efficacy results. The one trial to reach a conclusion (COVID-19) was stopped early for futility. |
Read top to bottom, that table tells a story of expectations meeting reality. The first-in-human study (Hickson 2019) was a genuine milestone: in nine people with diabetic kidney disease, a three-day course of D+Q measurably reduced senescent-cell markers in fat and skin. That proved the mechanism can work in humans, which is real and important, but it measured cells, not kidneys, health, or survival.
The next study (Justice 2019) tested D+Q in fourteen people with idiopathic pulmonary fibrosis, a serious lung disease, and reported that participants walked farther and got out of a chair faster afterward. That sounds like function, but it was an open-label pilot with no placebo group, so the gains could partly reflect encouragement, practice, or expectation. And notably, the lung disease itself did not improve. The crucial test came in 2023, when the same kind of trial was repeated with a placebo group (Nambiar 2023). The result is the honest heart of this whole field: with a control arm in place, the physical-function benefit did not reproduce, and the D+Q group had more side effects.
It kept going. An Alzheimer's pilot (Gonzales 2023) in five patients confirmed that dasatinib crosses into the brain but found no change in amyloid, tau, senescence markers, or cognition. And the best-designed trial to date, a phase 2 randomized controlled trial in sixty postmenopausal women (Farr 2024), missed its primary endpoint: the main bone-turnover marker did not differ from the control group. A hint of benefit showed up only when researchers looked afterward at the subgroup with the highest senescent-cell burden, which is a hypothesis to test next, not a result to bank.
The fisetin problem no one mentions
Now the part that should stop any fisetin shopper in their tracks. Everything in that scoreboard used dasatinib plus quercetin, not fisetin. Fisetin has no published human efficacy results at all.
The most-hyped senolytic has the least human data
Several fisetin trials are registered, including well-known frailty trials at the Mayo Clinic, but as of 2026 none has published results showing fisetin clears senescent cells or improves anything in people. The main readouts simply are not out yet.
Worse, the one fisetin trial to reach a firm conclusion, a small pilot of about 20 nursing-home residents with COVID-19, was terminated early for futility. So the compound with the loudest marketing and the biggest shelf presence is, on the human evidence, the least proven of the bunch. When a seller says fisetin is "a senolytic shown to extend lifespan," they are quoting a mouse.
Dose, absorption, and the strawberry myth
Even setting proof aside, the practical questions of how much and whether it is absorbed are unresolved. The popular "hit and run" fisetin protocol, roughly 1000 to 1500 mg on two consecutive days, repeated every so often, is not a clinically established regimen. It matches the human dose the Mayo Clinic trials chose, about 20 mg per kilogram on two days, which for a typical adult lands in that gram-level range. That human dose was informed by the mouse work, where fisetin was given at higher amounts per kilogram (on the order of 100 mg/kg), but it is a trial-selected starting point, not a dose proven to do anything in people.
Two facts make the dose even murkier. First, ordinary oral fisetin is poorly absorbed: it barely dissolves in water, is rapidly broken down and cleared, so blood levels from a standard capsule are low and short-lived, and the tissue exposure a supplement user actually gets is unknown. That is exactly why "enhanced absorption" liposomal products exist, though better blood levels have not been shown to translate into any human benefit. Second, you cannot eat your way there: a cup of strawberries contains at most a few tens of milligrams of fisetin, so reaching a gram-level trial dose would mean eating pounds of them, and the "eat more berries for senolysis" idea does not survive the arithmetic.
Safety, and a serious warning about D+Q
The safety story splits cleanly in two, and conflating the two halves is the most dangerous mistake in this space.
Fisetin is a flavonoid found in food, and at ordinary supplement doses it is generally considered low-risk and was well tolerated in the short courses used in trials, with mild stomach upset or headache possible. That said, high-dose, long-term safety in humans has not been established, flavonoids can affect drug-metabolizing enzymes and may interact with blood thinners and other medications, and supplement purity is not guaranteed. Low-risk as a food component is not the same as proven safe at senolytic megadoses taken for years.
Do not attempt dasatinib plus quercetin on your own
Dasatinib is a prescription chemotherapy drug (a tyrosine-kinase inhibitor used for leukemia), not a wellness supplement. It carries serious risks that require medical supervision, including effects on blood counts, fluid buildup around the lungs and heart, bleeding, and cardiovascular effects. Even in carefully monitored trials, D+Q caused more side effects than placebo.
All of the human senolytic evidence comes from tightly supervised clinical trials in patients who had a specific disease, not from healthy people chasing longevity. Sourcing and self-dosing dasatinib to copy a trial protocol is the highest-risk mistake in this field. If you are curious about senolytics, the right move is a conversation with a physician, not an online pharmacy.
So should you try fisetin?
Here is a straight answer rather than a dodge. Fisetin at typical supplement doses is low-risk to try as an antioxidant flavonoid, so if you want to take it while the science matures, that is a defensible personal choice, as long as you go in clear-eyed: you are taking an under-absorbed flavonoid with no proven human longevity benefit, not a validated anti-aging therapy. Keep expectations at the level the evidence supports, which right now is roughly zero for hard outcomes. What you should not do is self-experiment with dasatinib, and you should not pay premium prices believing fisetin is a proven "clear your zombie cells" treatment.
It is also worth knowing what would genuinely change the picture, so you can watch for it. The honest skeptic's checklist is short: a placebo-controlled fisetin trial that shows it actually reduces senescent-cell markers in people; the delayed Mayo frailty readouts reporting real function benefits; and, eventually, any trial with a hard endpoint rather than a surrogate. Until one of those lands, fisetin remains a promising lab compound marketed as a longevity therapy. If you are exploring this whole category, our broader longevity supplements overview and our looks at spermidine and NMN and NAD+ apply the same evidence-first lens to the other popular candidates.
Fisetin products, honestly
If you have read this far and still want to try fisetin as a low-risk experiment, the picks below are real, currently sold options at a range of doses and formats. Two honest framings apply to all of them: no fisetin product is a proven senolytic in people, and the common 100 mg capsules sit far below the gram-level intermittent doses used in the mouse studies and the (still unpublished) human trials.
Whichever you pick, keep the frame from this article in mind: you are buying a low-risk flavonoid with encouraging mouse data and no proven human longevity effect, and no capsule on the market has been shown to do in a person what senolytics do in a mouse.
Frequently asked questions
Do senolytics work in humans?
There are encouraging early signals, but nothing close to proof. A handful of small human trials of dasatinib plus quercetin have shown the approach can reduce markers of senescent cells and is feasible to run, but the trials are tiny (5 to 60 people), short (days to weeks of dosing), and measured surrogate markers or short-term physical tests, not lifespan or health outcomes. When a placebo group was added to one trial, an earlier physical-function benefit did not hold up, and the only phase 2 randomized trial missed its main goal. So senolytics are a promising idea with real first human data on safety and biomarkers, not a proven way to live longer or healthier.
Does fisetin extend lifespan in humans?
No, that has not been shown, and no human trial has even measured it. Lifespan extension from fisetin was reported in aged mice in a 2018 study, and that mouse result is the source of nearly all the excitement. In people, there are no published trials showing fisetin extends lifespan, improves healthspan, or clears senescent cells. The human fisetin trials that exist are still unpublished or, in one case, were stopped early for futility. Anyone telling you fisetin is proven to make humans live longer is describing a mouse study.
Are there any published human trials of fisetin?
As of 2026, no fisetin senolytic trial has published efficacy results. Several are registered (including Mayo Clinic frailty trials), but their main readouts are not yet reported, and the one fisetin trial to reach a conclusion, a small pilot in nursing-home residents with COVID-19, was terminated early for futility. This is the single most surprising fact in the field: fisetin is the most-hyped over-the-counter senolytic, yet the published human senolytic results that do exist come from dasatinib plus quercetin, not from fisetin.
What is the difference between fisetin and dasatinib plus quercetin?
Fisetin is a plant flavonoid you can buy over the counter, found in small amounts in strawberries and apples. Dasatinib plus quercetin (often written D+Q) is the combination used in almost all human senolytic trials, and it is a different animal: dasatinib is a prescription leukemia chemotherapy drug with serious risks, paired with the flavonoid quercetin. So the compound with the most human data (D+Q) is not something you can or should buy and take yourself, while the compound you can buy (fisetin) has essentially no published human efficacy data. That gap is the heart of the story.
How much fisetin do you need, and can you get it from strawberries?
You cannot get a meaningful senolytic dose from food. A cup of strawberries contains at most a few tens of milligrams of fisetin, so reaching the gram-level doses used in the trials would mean eating pounds of berries, which is not realistic. The human trials use about 20 mg per kilogram on two consecutive days, which for a typical adult is roughly 1000 to 1500 mg. That amount was chosen for the trials, not proven to do anything in people, and oral fisetin is poorly absorbed, so how much actually reaches your tissues is uncertain. There is no established, validated human dose.
Are senolytics safe?
It depends entirely on which one. Fisetin is a food flavonoid and at ordinary supplement doses it is generally low-risk and was well tolerated in the short courses used in trials, though high-dose long-term safety is unknown and it may interact with some medications. Dasatinib plus quercetin is a different matter: dasatinib is a prescription chemotherapy drug with serious potential side effects, including effects on blood counts, fluid around the heart and lungs, and the cardiovascular system, and even in supervised trials D+Q caused more side effects than placebo. Do not attempt D+Q on your own. Anyone considering either should talk with a physician.
The bottom line
Senolytics deserve their reputation as one of the most promising ideas in aging biology, and the mouse data are genuinely impressive: clearing senescent cells, whether with a genetic switch or with drugs, has extended lifespan and healthspan in animals, and fisetin was the standout flavonoid in those screens. But promise is not proof, and the human story is early and humbling. Every published human trial used dasatinib plus quercetin rather than fisetin, enrolled between five and sixty people, and measured cell markers or short-term function over days to weeks. The one placebo-controlled function trial did not confirm the early benefit, the Alzheimer's pilot found nothing, and the best-designed randomized trial missed its primary endpoint. No human has ever been shown to live longer or healthier from a senolytic, and fisetin specifically, the one on the shelf, has no published human efficacy data and is poorly absorbed to boot. Fisetin is low-risk to try as a flavonoid if you want to, but treat it as an experiment, not a therapy. Do not self-dose dasatinib. And watch for the pending trial readouts, because this is a field where the honest verdict could genuinely improve, it just has not yet. For the wider category, see our longevity supplements guide.